D
Djahida Bedja
Researcher at Johns Hopkins University
Publications - 124
Citations - 12306
Djahida Bedja is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pressure overload & Heart failure. The author has an hindex of 50, co-authored 122 publications receiving 10817 citations. Previous affiliations of Djahida Bedja include Australian School of Advanced Medicine & Macquarie University.
Papers
More filters
Journal ArticleDOI
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
Jennifer P Habashi,Daniel P. Judge,Tammy M. Holm,Ronald D. Cohn,Bart Loeys,Timothy K. Cooper,Loretha Myers,Erin C Klein,Guosheng Liu,Carla L. Calvi,Megan Podowski,Enid Neptune,Marc K. Halushka,Djahida Bedja,Kathleen L. Gabrielson,Daniel B. Rifkin,Luca Carta,Francesco Ramirez,David L. Huso,Harry C. Dietz +19 more
TL;DR: Losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with Marfan syndrome and has the potential to prevent the major life-threatening manifestation of this disorder.
Journal ArticleDOI
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
Eiki Takimoto,Hunter C. Champion,Manxiang Li,Diego F. Belardi,Shuxun Ren,E. Rene Rodriguez,Djahida Bedja,Kathleen L. Gabrielson,Yibin Wang,David A. Kass +9 more
TL;DR: It is shown that blocking the intrinsic catabolism of cGMP with an oral phosphodiesterase-5A (PDE5A) inhibitor (sildenafil) suppresses chamber and myocyte hypertrophy, and improves in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction.
Journal ArticleDOI
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
Georg Feldmann,Surajit Dhara,Volker Fendrich,Djahida Bedja,Robert Beaty,Michael Mullendore,Collins Karikari,Hector A Alvarez,Christine A. Iacobuzio-Donahue,Antonio Jimeno,Kathleen L. Gabrielson,William Matsui,Anirban Maitra +12 more
TL;DR: By targeting specific cellular subpopulations likely involved in tumor initiation at metastatic sites, Hh inhibitors may provide a new paradigm for therapy of disseminated malignancies, particularly when used in combination with conventional antimetabolites that reduce "bulk" tumor size.
Journal ArticleDOI
TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome
Connie M. Ng,Alan Cheng,Loretha Myers,Francisco Martinez-Murillo,Chunfa Jie,Djahida Bedja,Kathleen L. Gabrielson,Jennifer M.W. Hausladen,Robert P. Mecham,Daniel P. Judge,Harry C. Dietz,Harry C. Dietz +11 more
TL;DR: In this article, the authors showed that increased TGF-beta signaling may contribute to the multisystem pathogenesis of Marfan syndrome, including the development of myxomatous changes of the atrioventricular valves.
Journal ArticleDOI
Noncanonical TGFβ Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice
Tammy M. Holm,Jennifer P Habashi,Jefferson J. Doyle,Djahida Bedja,Yichun Chen,Christel Van Erp,Mark E. Lindsay,David Kim,Florian Schoenhoff,Ronald D. Cohn,Bart Loeys,Craig J. Thomas,Samarjit Patnaik,Juan J. Marugan,Daniel P. Judge,Harry C. Dietz +15 more
TL;DR: Noncanonical (Smad-independent) TGFβ signaling is a prominent driver of aortic disease in MFS mice, and inhibition of the ERK1/2 or JNK1 pathways is a potential therapeutic strategy for the disease.